NCT04421560 2026-02-20
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT03734198 2025-11-26
IDA53
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT02956382 2025-07-18
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
Phase 1/2 Completed
NCT03679624 2023-10-23
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02309580 2023-05-09
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02419560 2022-05-24
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
University of Virginia
Phase 1 Completed
NCT02356458 2022-03-11
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 1/2 Terminated
NCT03617484 2020-06-22
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01614821 2020-01-21
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02269085 2019-02-28
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Terminated